Biochem/physiol Actions

Target IC₅₀: 10.7 µM inhibiting Rho-associated kinase (ROCK)

Reversible: yes

Product competes with ATP.

Cell permeable: yes

Target K_i: .6 µM, 1.6 µM, 36 µM, inhibiting protein kinase A, protein kinase G, myosin light chain kinase, respectively

Primary TargetPKA

General description

A cell-permeable, reversible, and ATP-competitive Ca²⁺ antagonist with anti-vasospastic properties. Inhibits protein kinase A (K_i = 1.6 µM), protein kinase G (K_i = 1.6 µM), and myosin light chain kinase (K_i = 3.6 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC₅₀ = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.

A cell-permeable, reversible, and ATP-competitive Ca²⁺ antagonist with anti-vasospastic properties. Inhibits protein kinase A (K_i = 1.6 µM), protein kinase G (K_i = 1.6 µM), and myosin light chain kinase (K_i = 36 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC₅₀ = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Watanabe, K., et al. 2007. Nature Biotech.25, 681.Swärd, K., et al. 2000. J. Physiol.522, 33.Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.Seto, M., et al. 1991. Eur. J. Pharmacol.195, 267.Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther.259, 738.Asano, T., et al. 1990. Eur. J. Pharmacol.190, 365.Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun.171, 1182.Asano, T., et al. 1989. Br. J. Pharmacol. 98,1091.

Packaging

1 mg in Plastic ampoule

Reconstitution

Following reconstitution, refrigerate (4°C). Aqueous stock solutions are stable for up to 6 months at 4°C.

Warning

Toxicity: Harmful (C)